Arkolith/Insider Trading/IKT/Form 4

Lees-Rolfe Garth

Chief Financial OfficerInhibikase Therapeutics, Inc. (IKT) · full profile →Form 4 · filed Jan 7, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
0 non-derivative · 3 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 3, 2025Grant(A)433K—$0433K
Jan 3, 2025Grant(A)471K—$0471K
Jan 3, 2025Grant(A)235K—$0235K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-003130) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML